The estimated Net Worth of Eric Wei is at least $319 Tisíc dollars as of 7 February 2017. Eric Wei owns over 6,575 units of Caladrius Biosciences Inc stock worth over $74,056 and over the last 9 years Eric sold CLBS stock worth over $244,786.
Eric has made over 8 trades of the Caladrius Biosciences Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Eric sold 6,575 units of CLBS stock worth $31,363 on 7 February 2017.
The largest trade Eric's ever made was selling 87,500 units of Caladrius Biosciences Inc stock on 30 June 2016 worth over $52,500. On average, Eric trades about 26,100 units every 21 days since 2016. As of 7 February 2017 Eric still owns at least 172,223 units of Caladrius Biosciences Inc stock.
You can see the complete history of Eric Wei stock trades at the bottom of the page.
Eric's mailing address filed with the SEC is 106 Allen Rd #203, Basking Ridge, NJ 07920, USA.
Over the last 9 years, insiders at Caladrius Biosciences Inc have traded over $244,786 worth of Caladrius Biosciences Inc stock and bought 202,695 units worth $275,173 . The most active insiders traders include Richard J Berman, Steven M Klosk a Peter G Traber. On average, Caladrius Biosciences Inc executives and independent directors trade stock every 178 days with the average trade being worth of $17,064. The most recent stock trade was executed by Steven S Myers on 8 December 2021, trading 33,785 units of CLBS stock currently worth $30,069.
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. It is developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Its technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication. The Company’s current product candidates include: HONEDRA® (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; OLOGO™ (formerly CLBS14), a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”); CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); CLBS119, an emergent CD34+ stem cell therapy responding to the COVID-19 pandemic and the potentially permanent damage the virus inflicts on the lungs of many patients; and CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for chronic kidney disease (“CKD”).
Caladrius Biosciences Inc executives and other stock owners filed with the SEC include: